Through a multi-institutional effort led by the Japan Society for Gastroenterological Carcinogenesis, a combination of p53/MMP-7 expression was found to be a promising factor to predict outcome of Stage II/III gastric cancer, and possibly to help select the treatment for Stage II cancer, thus supplementing the conventional TNM system. Here, MMP7 is linked to cancer.